Biontech SE (($CC:BNTX.CUR)), Genmab (Otc) ((GMAB)), Biontech Se Sponsored Adr ((BNTX)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioNTech SE and Genmab have launched a pivotal clinical study titled ‘A First-in-Human, Open-label, Dose-finding Trial to Evaluate the Safety and Antitumor Activity of GEN1056 in Subjects With Advanced Solid Tumors.’ This study aims to assess the safety and preliminary antitumor activity of GEN1056 in patients with advanced solid tumors who have no standard treatment options. The trial is significant as it seeks to establish a recommended dose for future studies, potentially offering new hope for patients with limited options.
The intervention under investigation is GEN1056, a biological treatment administered via intravenous infusion. Its primary purpose is to evaluate safety and antitumor activity, with the ultimate goal of determining an optimal dosing schedule for further clinical trials.
The study follows an interventional design with a sequential intervention model and no masking. It is primarily focused on treatment, with the trial divided into two parts: dose escalation and dose schedule optimization.
Key dates for the study include its start on October 24, 2022, and the last update on August 4, 2025. These dates are crucial as they mark the progression and updates of the trial, providing a timeline for stakeholders to track its development.
The market implications of this study could be significant for BioNTech SE and Genmab, as positive results may boost investor confidence and stock performance. In a competitive landscape, advancements in cancer treatment can differentiate companies and enhance their market position.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.